Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Cancer Metastatic
Interventions: DRUG: Niraparib|DRUG: Aromatase Inhibitors
Sponsor: MedSIR
Collaborators: GlaxoSmithKline